精彩内容5月29日,国家药监局官网发布了11则药品获批(含附条件批准)公告,包括了4个生物药1类新药和7个化药1类新药,从一级集团来看,恒瑞医药占了3个,“创新药一哥”实至名归。2024年在中国三大终端六大市场,化学药及生物药合计销售规模在12000亿元左右,11款新药获批将掀起市场新的风浪。表1:最新获批(含附条件批准)的新药来源:国家药监局官网、米内网制表图1:中国三大终端六大市场化学药及生物...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.